Home › Research › Long-term cohort studies
Plasma amyloid-β and risk of Alzheimer's disease in the Framingham Heart Study
Chouraki V, Beiser A, Younkin L, Preis SR, Weinstein G, Hansson O, Skoog I, Lambert JC et al.. Alzheimer's & dementia : the journal of the Alzheimer's Association, 2014-09-10
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Background Plasma amyloid-β (Aβ) peptide levels have been examined as a low-cost accessible marker for risk of incident Alzheimer's disease (AD) and dementia, but results have varied between studies. We reassessed these associations in one of the largest, prospective, community-based studies to date. Methods A total of 2189 dementia-free, Framingham Study participants aged >60 years (mean age, 72 ± 8 years; 56% women) had plasma Aβ1-42 and Aβ1-40 measured and were followed prospectively (mean, 7.6 ± 3.0 years) for dementia/AD.
What this study adds
Evidence grade: Low
This is a pooled review of 2,189 participants. This study found that higher plasma amyloid-β1-42 levels were associated with lower risk of dementia in older adults followed for about 7.6 years. It is observational and does not show that measuring or altering plasma amyloid-β prevents Alzheimer's disease.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Chouraki, V., Beiser, A., Younkin, L., Preis, SR., Weinstein, G., Hansson, O., et al. (2015). Plasma amyloid-β and risk of Alzheimer's disease in the Framingham Heart Study. Alzheimer's & dementia : the journal of the Alzheimer's Association. https://doi.org/10.1016/j.jalz.2014.07.001
Vancouver
Chouraki V, Beiser A, Younkin L, Preis SR, Weinstein G, Hansson O, et al. Plasma amyloid-β and risk of Alzheimer's disease in the Framingham Heart Study. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2015. doi:10.1016/j.jalz.2014.07.001. PMID: 25217292.
BibTeX
@article{chouraki2015-25217292,
author = {Chouraki, V. and Beiser, A. and Younkin, L. and Preis, SR. and Weinstein, G. and Hansson, O. and Skoog, I. and Lambert, J. C. and others},
title = {{Plasma amyloid-β and risk of Alzheimer's disease in the Framingham Heart Study}},
journal = {Alzheimer's \& dementia : the journal of the Alzheimer's Association},
year = {2015},
doi = {10.1016/j.jalz.2014.07.001},
pmid = {25217292},
url = {https://doi.org/10.1016/j.jalz.2014.07.001}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- We reassessed these associations in one of the largest, prospective, community-based studies to date.
- Methods A total of 2189 dementia-free, Framingham Study participants aged >60 years (mean age, 72 ± 8 years; 56% women) had plasma Aβ1-42 and Aβ1-40 measured and were followed prospectively (mean, 7.6 ± 3.0 years) for dementia/AD.
- Results Increased plasma Aβ1-42 levels were associated with lower risk of dementia (Aβ1-42: hazard ratio [HR] = 0.80 [0.71‒0.90], P Conclusion Our results suggest that lower plasma Aβ levels are associated with risk of incident AD and dementia.
- They encourage further evaluation of plasma Aβ levels as a biomarker for risk of developing clinical AD and dementia.
Why it matters
This study found that higher plasma amyloid-β1-42 levels were associated with lower risk of dementia in older adults followed for about 7.6 years. It is observational and does not show that measuring or altering plasma amyloid-β prevents Alzheimer's disease.
Study details
- Participants2,189
- Evidence strengthLow
How this study scored 68/100
Published in a leading specialty journal, and it is a meta-analysis pooling many studies. Scored zero for effect reported because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Alzheimer's & dementia : the journal of the Alzheimer's Association) |
| Journal's citation record | 2 / 4 | Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29) |
| Study design | 12 / 12 | A meta-analysis pooling many studies (from PubMed type “Meta-Analysis”) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2015 — within 20 year(s) of the newest study here |
| Sample size | 3 / 4 | 2,189 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | A review of other studies — randomization is not credited here |
| Times cited | 5 / 7 | Cited 121 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 9.3 citations a year over 13 year(s) since 2015 |
| Impact for its field and year | 3 / 6 | Cited 6.3× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 9 other studies in this library |
| Still being cited | 2 / 4 | Cited 23 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 4 / 4 | Last-listed author Sudha S. Seshadri: h-index 148 (OpenAlex, whole career) |
| Institution's track record | 3 / 3 | National Institutes of Health: institution h-index 2,723 (OpenAlex) |
| Multicenter collaboration | 3 / 3 | OpenAlex lists 11 institution(s) in 3 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 25217292) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 68 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 20.
Later studies that cite this one
9 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in Long-term cohort studies from nearby years
Also tagged “precursor”
1,337 studies in the library carry the topic tag “precursor”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,337 tagged studies.